Silverback Therapeutics (SBTX) Competitors $9.41 -0.55 (-5.52%) As of 09/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. CALT, ZYME, MBX, AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, and ELYMShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and Eliem Therapeutics (ELYM). Silverback Therapeutics vs. Its Competitors Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Eliem Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation. Which has preferable earnings and valuation, CALT or SBTX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Silverback Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Silverback TherapeuticsN/AN/A-$89.48M-$2.42-3.89 Do institutionals & insiders hold more shares of CALT or SBTX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer CALT or SBTX? In the previous week, Calliditas Therapeutics AB (publ) had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Calliditas Therapeutics AB (publ) and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 beat Calliditas Therapeutics AB (publ)'s score of -0.71 indicating that Silverback Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Negative Silverback Therapeutics Neutral Which has more volatility and risk, CALT or SBTX? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Is CALT or SBTX more profitable? Silverback Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Silverback Therapeutics' return on equity of -29.62% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Silverback Therapeutics N/A -29.62%-28.20% SummaryCalliditas Therapeutics AB (publ) and Silverback Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$339.31M$852.55M$5.74B$10.30BDividend YieldN/A4.84%5.89%4.62%P/E Ratio-3.891.2276.6926.52Price / SalesN/A123.38444.6987.66Price / CashN/A19.5637.2260.63Price / Book1.276.5813.596.31Net Income-$89.48M-$4.18M$3.29B$271.37M7 Day Performance-10.38%-0.59%-0.69%0.59%1 Month Performance-35.24%14.20%3.85%6.22%1 Year Performance-27.89%18.60%81.84%28.35% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$9.41-5.5%N/A-27.3%$339.31MN/A-3.8983High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4923 of 5 stars$15.23+0.3%$21.43+40.7%+29.0%$1.14B$122.87M-10.15460Positive NewsMBXMBX Biosciences2.8244 of 5 stars$11.42+4.8%$37.63+229.5%N/A$383.64MN/A-2.5236Positive NewsAVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-89.3%$216.81MN/A-2.5020Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-56.7%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.135 of 5 stars$4.98-2.2%N/AN/A$178.53M$3.86M0.00N/ACYBNCybin2.69 of 5 stars$6.43+2.6%$85.00+1,221.9%N/A$151.68MN/A-1.4750High Trading VolumeVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,313.5%$94.36MN/A-18.155WHWKWhitehawk Therapeutics1.168 of 5 stars$1.80+0.6%N/AN/A$84.83M$25.98M-30.0021Positive NewsELYMEliem TherapeuticsN/A$2.47+3.3%N/A-74.7%$73.49MN/A-4.669 Related Companies and Tools Related Companies CALT Alternatives ZYME Alternatives MBX Alternatives AVTE Alternatives NLTX Alternatives BIOA Alternatives CYBN Alternatives VIRI Alternatives WHWK Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
